Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
spinal muscular atrophy
Pharma
Biogen undeterred after FDA snub for high-dose Spinraza in SMA
Despite possessing solid data on high-dose Sprinraza in spinal muscular atrophy, Biogen must revise its application if it hopes to secure an approval.
Fraiser Kansteiner
Sep 24, 2025 9:51am
Issues at Novo site delay Scholar Rock's bid for SMA approval
Sep 23, 2025 9:19am
Novartis campaign celebrates every milestone for teens with SMA
Jul 11, 2025 8:19am
Novartis peels back Zolgensma IT data in older SMA patients
Mar 19, 2025 9:00am
Roche picks up FDA nod for easier Evrysdi dosing format in SMA
Feb 12, 2025 2:30pm
Novartis readies intrathecal Zolgensma for older SMA patients
Jan 2, 2025 12:30pm
